Morgan Stanley lowered the firm’s price target on Avantor (AVTR) to $12 from $15 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says bio processing headwinds led to a “disappointing” quarter. It expects completive headwinds to pressure Avantor’s Lab Solutions margins.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Avantor Reports Q2 2025 Financial Results
- Avantor’s Earnings Call: Mixed Sentiments and Strategic Moves
- Avantor’s Market Uncertainty: Hold Rating Amid Pricing Pressures and Leadership Transition
- Avantor downgraded to Hold at Jefferies on fading turnaround hopes
- Avantor downgraded to Hold from Buy at Jefferies